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Abstract
Background Breast tissue expression of the ERBB  proto-
oncogene family has been extensively studied. It was recently
shown that expression of epidermal growth factor receptor
(EGFR; c-erbB-1) and epidermal growth factor receptor (HER)2
(c-erbB-2) can be detected in the serum of breast cancer
patients. The clinical relevance of this has not been fully
established.
Methods EGFR and HER2 immunoassays were conducted in
blood from 57 patients in whom paired serum samples were
available (from the times of primary and metastatic diagnoses),
from 96 primary breast cancer patients and from 49 normal
individuals. Of the 57 patients with paired serum samples,
paired tissue samples for HER2 expression were available for
eight.
Results Serum levels of EGFR serum levels were significantly
higher in normal individuals (median 75.3 ng/ml, range 43.2 to
114.2 ng/ml) than in patients with primary breast cancer
(median 59.3 ng/ml, range 21.3 to 94.1 ng/ml; P < 0.001). In
the paired serum samples, EGFR levels decreased significantly
between the time of primary diagnosis (median 56.3 ng/ml,
range 29.1 to 142.7 ng/ml) and metastatic diagnosis (median
30.9 ng/ml, range 10.9 to 106.4 ng/ml; P < 0.001). In six (11%)
a change occurred from over-expression (>78 ng/ml) to normal
expression. In contrast, no significant difference was seen in
HER2 serum levels in normal individuals (median 12.2 ng/ml,
range 7.8 to 20.9 ng/ml) and primary breast cancer patients
(median 12.5 ng/ml, range 6.9 to 122.2 ng/ml; P = 0.511).
However, in the paired serum samples, HER2 levels increased
significantly between the time of primary (median 12.2 ng/ml,
range 5.7 to 85.0 ng/ml) and metastasis (median 17.7 ng/ml,
range 6.3 to 3,337.4 ng/ml; P < 0.001). HER2 over-expression
(>15 ng/ml) was observed in 16 out of 57 patients (28%) at
primary breast cancer diagnosis and in 31 out of 57 (54%) at
metastasis. In 18 patients (32%) HER2 expression changed
from normal to over-expression.
Conclusion Decisions regarding the use of targeted therapies
in the metastatic setting are often based on the oncogene
expression of the primary tumour. Our results suggest that
serum oncogene assessments may be complementary to this
and could potentially widen the indications for these beneficial
therapies.
Introduction
The erbB (human epidermal growth factor receptor [HER]/neu
1 to 4) receptors are a family of four known receptors localized
on the cell membrane of most tumours, including breast can-
cer. These receptors are activated by various ligands that trig-
ger a network of signalling pathways, leading to increased
uncontrolled growth of cancer cells and unfavourable progno-
sis. The over-expression of EGFR (erbB-1 receptor) is seen in
20% to 81% of breast tumours, whereas HER2 receptor over-
expression is seen in approximately 20% [1-4].
The extracellular binding region of these two receptors for
EGFR and HER2 are proteolytically released from the cell sur-
face upon receptor activation and can be detected in patients'
CA = cancer antigen; CEA = carcinoembryonic antigen; EGFR = epidermal growth factor receptor; ER = oestrogen receptor; HER = human epider-
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serum. The relevance of the serum expression of these pro-
teins has been the subject of a number of studies [5-7]. Early
studies conducted by Mansour and coworkers [8] showed
that serum HER2 levels were significantly higher in patients
with breast cancer than in patients with benign breast dis-
eases and in normal control individuals. Also, in this group of
breast cancer patients, serum HER2 positivity was a signifi-
cant prognostic factor [8]. Others showed that serum HER2
positivity was significantly more common in patients with
recurrent breast cancer than in those with primary breast can-
cer, and that there was a good association between HER2 tis-
sue expression and serum HER2 levels [9]. Measuring this
protein in the serum could provide an easier and more acces-
sible method of diagnosing patients who may benefit from tar-
geted therapies (trastuzumab) as compared with assessment
of tissue expression. Also, it has opened the possibility of
measuring the 'real-time' expression of this oncogene, which
may be useful in assessing treatment effects [10,11].
The potential role for serum EGFR assessments in breast can-
cer is not quite as clear, however. Although raised pretreat-
ment levels have been shown to be associated with decreased
progression-free and overall survival in metastatic breast can-
cer patients [6,12], several studies have shown that patients
with some solid epithelial cancers in fact exhibit decreased lev-
els of serum EGFR compared with healthy control individuals
[6,13]. The biological background and the clinical relevance of
these observations are not yet known.
Presently anti-EGFR/HER2 therapy for recurrent/metastatic
breast cancer is based on immunohistochemistry and fluores-
cence in situ hybridization of the primary breast cancer tissue
[14]. Still, the value of the serum expression of these markers
in predicting response to such therapies remains largely
unclear. In the present study, we analyzed serum expression of
EGFR and HER2 in paired samples (at time of primary diagno-
sis and at metastasis) and we aimed to correlate this with the
tissue expression. Furthermore, we analyzed the serum
expression of these markers in an unselected group of healthy
individuals and consecutive breast cancer patients diagnosed
in our unit. Finally, the association of these with tumour mark-
ers carcinoembryonic antigen (CEA) and cancer antigen
(CA)15.3 was determined.
Materials and methods
Patients
Between October 1992 and October 2004, 57 patients were
identified from whom paired blood samples were available for
analysis (both at diagnosis of primary breast cancer [PBC] and
at metastasis). Blood samples were collected from patients
attending breast clinics who gave written, informed consent
under a study protocol approved by the institutional ethics
committee. Blood specimens were allowed to stand before
being centrifugated at 1,250 g for 5 minutes, serum removed
and stored at -20°C.
Furthermore, preoperative serum samples were collected from
96 PBC patients and 49 healthy individuals attending the
National Health Service Breast Screening Programme and
had a normal mammography or were attending a symptomatic
breast clinic and discharged with no detected abnormality fol-
lowing triple assessment (age range 19 to 71 years, mean age
54 years). All PBC and normal samples from healthy individu-
als were collected during a 12-month period in 2004. Of the
57 patients with paired blood samples, paired tissue samples
(primary and metastasis) were also available from 8.
Clinical data were collected from the unit's database, which
was prospectively updated (following each clinic consulta-
tion). Any change in a patient's treatment or progress was
entered into our database.
Methods
Serum EGFR and HER2 estimation was done using Bayer
microtitre Immunoassays (ADVIA Centaur® Immunoassay sys-
tem, Bayer Healthcare Diagnostics Divisions, Bayer House,
Strawberry Hill, Newbury BERK, RG14 1JA, UK). The normal
range for EGFR was 45 to 78 ng/ml and for HER2 it was
under 15 ng/ml (based on the mean value of healthy individual
± 2 standard deviations). Tissue HER2 expression was esti-
mated using the HercepTest kit protocol (Dako Ltd, Denmark
House, Angel Drove, Ely, Cambridgeshire, CB7 4ET, UK). The
immunohistochemical expression was quantified as 0, 1+, 2+,
or 3+. HER2 positivity was defined as 3+. Tissue EGFR immu-
nohistochemistry was performed with mouse monoclonal anti-
bodies against EGFR in accordance with the protocol
provided by Novocastra Ltd and the expression was scored
according to the percentage of cells exhibiting either mem-
brane or cytoplasmic staining (Novocastra Laboratories Ltd,
Newcastle upon Tyne, NE12 8EW, UK). The cut-off for posi-
tive expression was defined as 10% or more of cells stained.
Serum CA15.3 and CEA estimation was done using Auto-
mated Immunoassay on the Bayer Centaur Immunoassay ana-
lyzer. The normal range for CA15.3 was 0 to 35 kU/l and for
CEA it was 0 to 5 kU/l.
Tumour grade was assessed using the Nottingham method
[15]. Lymph node stage was determined from the results of
axillary node sampling or dissection. For patients diagnosed
with primary breast cancer before 1995, oestrogen receptor
(ER) activity was measured using the standard radioligand
binding assay on tissue cytosol samples, with the threshold for
designation of ER positivity being 10 fmol/mg of protein. Since
then, ER status has been determined using immunocytochem-
ical methods. An H-score above 50 has been used to identify
ER positive tumours for adjuvant endocrine therapy.
Statistical analysis
Statistical analysis was performed with the SPSS software
package (version 12.0 for Windows; SPSS Inc., Burlingame,
CA, USA). Because the distribution of serum EGFR andAvailable online http://breast-cancer-research.com/content/9/6/R75
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serum HER2 levels was nonparametric, the Mann-Whitney
test was used to compare median values. χ2 analysis and
Fisher's exact were used to compare numbers in each group.
A  P  value of less than 0.05 was considered statistically
significant.
Results
EGFR and HER2 serum expression in healthy individuals 
versus breast cancer patients
Healthy individuals had significantly higher serum EGFR levels
(median 75.3 ng/ml, range 43.2 to 114.2 ng/ml) than did the
PBC patients (median 59.3 ng/ml, range 21.3 to 94.1 ng/ml;
U = 3,599.0, P < 0.001)). For serum HER2, no significant dif-
ference was observed between the healthy individuals and
PBC patients (median 12.2 ng/ml, range 7.8 to 20.9 ng/ml
and median 12.5 ng/ml, range 6.9 to 122.2 ng/ml, respec-
tively; U = 2,383.5, P = 0.511). Ten out of 96 (10.4%) PBC
patients had serum EGFR levels above the reference range
(45 to 78 ng/ml), as compared with 20 out of 49 (40.8%)
healthy individuals. For serum HER2 (reference range < 15
ng/ml), the respective numbers were 22 out of 96 (22.9%)
and 10 out of 49 (20.4%).
Tumour characteristics of patients for whom paired 
blood samples were available
The demographics of the 57 patients and their tumour charac-
teristics are shown in Table 1. The median interval between
primary and metastatic diagnosis was 23 months (range 5 to
132 months).
EGFR and HER2 serum levels at time of primary and 
subsequent metastatic diagnosis
EGFR levels were significantly higher at the time of primary
diagnosis (median 56.3 ng/ml, range 29.1 to 142.7 ng/ml)
than at the time of metastatic diagnosis (median 30.9 ng/ml,
range 10.9 to 106.4 ng/ml; U = 2168.0, P < 0.001). Eighteen
of the 57 patients (31.6%) had elevated serum EGFR levels at
primary diagnosis. In six (11%) a change occurred from over-
expression (>78 ng/ml) to normal expression (45 to 78 ng/ml).
No patient changed from normal expression at primary diagno-
sis to over-expression at metastasis (Figure 1).
The converse was true for HER2; the levels were significantly
higher at metastasis (median 12.2 ng/ml, range 5.7 to 85.0
ng/ml) than at presentation of PBC (median 17.7 ng/ml, range
6.3 to 3,337.4 ng/ml; P < 0.001). Sixteen of the 57 patients
(28.2%) had elevated serum HER2 at the time of primary diag-
nosis. In 18 (32%) a change occurred from normal expression
(<15 ng/ml) to over-expression (>15 ng/ml). In five (8.8%) a
change occurred in the opposite direction, whereas in 34
(59.6%) levels remained in the same group of expression (nor-
mal or overexpression) between event periods (Figure 1).
At diagnosis of metastasis, serum EGFR levels were elevated
(>78 ng/ml) in 12 patients (21.1%), whereas serum HER2
was elevated (>15 ng/ml) in 31 (54.4%). In seven patients
(12.3%) both markers were elevated.
Association between change in serum HER-2 and serum 
EGFR expression and adjuvant hormone therapy
Of 57 patients 35 were ER positive, and notes on assessment
of treatment were available for 28. Of these, 16 patients were
not receiving adjuvant hormone treatment; of remaining 12
were receiving tamoxifen (n = 10), goserelin and tamoxifen (n
= 1), or anastrozole (n = 1). Table 2 shows the association
between receiving or not receiving hormone treatment at the
time of metastatic diagnosis, and whether a change occurred
in serum HER2 or serum EGFR. Adjuvant hormone treatment
was significantly associated with no change (reduction) in
serum EGFR levels between primary diagnosis and metastasis
(P = 0.039). No such treatment effect was seen with regard to
serum HER2 levels.
HER2 and EGFR expression in tissue samples from primary 
and subsequent metastatic disease
Of the 57 patients from whom paired serum samples were
available (primary and metastatic), in only eight was metastatic
breast tissue available for analysis. The tissue obtained from
Table 1
Tumour characteristics where paired serum available
Characteristic Value
Tumour size T1 21 (36.8)
T2 30 (52.6)
T3 5 (8.8)
Not known 1 (1.8)
Grade 1 2 (3.5)
2 14 (24.6)
3 35 (61.4)
Not known 6 (10.5)
Lymph node status None 22 (38.6)
1 to 3 22 (38.6)
>3 10 (17.5)
Not known 3 (5.3)
NPI ≤3.4 5 (8.8)
3.5 to 5.4 23 (40.4)
>5.4 19 (38.3)
Not known 10 (17.5)
ER status Negative 22 (38.6)
Age (years) 53 (30–86)
Paired serum samples were available for 57 patients. Values 
expressed as n (%) apart from age, which is expressed as median 
(range). ER, oestrogen receptor; NPI, Nottingham Prognostic Index.Breast Cancer Research    Vol 9 No 6    Asgeirsson et al.
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these samples were as follows: three skin recurrences, four
regional recurrences and one in-breast recurrence. All five
patients with regional recurrences and in-breast recurrences
were also diagnosed with distant metastases at the same time.
Of these eight recurrences in total, seven had no HER2
expression at the time of primary diagnosis and one exhibited
over-expression (3+) on immunohistochemistry. Of these
seven with no HER2 tissue expression at primary diagnosis,
none exhibited a change in tissue expression at metastasis. In
only one of these seven was a change in serum HER2 expres-
sion from normal to over-expression observed between
events. The remaining patient with tissue over-expression at
both events exhibited a change in serum HER2 expression
between events (from normal to over-expression).
Only five tissue samples were available for EGFR tissue
expression analysis (one regional recurrence, three skin
recurrences and one in-breast recurrence). When membrane
staining was assessed, one of these five samples changed
from negative expression to positive (>10% of cells express-
ing EGFR). Cytoplasmic staining was unchanged in all five
samples (all five exhibited positive expression both at primary
Figure 1
EGFR and HER-2 serum levels EGFR and HER-2 serum levels. (a) Epidermal growth factor receptor (EGFR) and (b) human epidermal growth factor receptor (HER)2 serum levels 
at time of (1) primary and (2) metastatic diagnosis. sEGFR, serum EGFR; sHER2, serum HER2.
Table 2
The association between adjuvant hormone treatment and change in serum EGFR and serum HER2 levels
Change in serum EGFR Change in serum HER2
No Yes No Yes
On adjuvant treatment
N o 8888
Y e s 1 1 184
P = 0.039 P = 0.459
EGFR, epidermal growth factor receptor; HER, human epidermal growth factor receptor.Available online http://breast-cancer-research.com/content/9/6/R75
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diagnosis and metastasis), although an increase in the per-
centage of cells expressing EGFR was seen in two (of which
one also exhibited a change in membrane expression). In one
of these the cell expression changed from 40% to 60% and in
the other from 30% to 80%. Neither one of these samples
exhibited a difference in serum EGFR expression between pri-
mary diagnosis and metastasis, although two of the remaining
three exhibited a decrease in serum EGFR expression (from
over-expression to normal levels of expression).
Association between serum HER2 and EGFR expression 
and tumour marker expression at metastasis
Table 3 shows the serum levels of oncogene and tumour
marker expression at time of metastatic diagnosis. All four
markers were available for 50 patients. In 52% of the patients
(26/50) either tumour marker CA15.3 or CEA was elevated. In
64% (32/50) either HER2 or EGFR was elevated, and in 78%
(39/50) one of these four markers was elevated. There was a
significant association between a raised HER2 serum expres-
sion and raised serum levels of the tumour markers CA15.3 (P
= 0.019) and CEA (P = 0.005; Table 4). Such an association
was not observed between EGFR serum expression and these
tumour markers (Table 4).
Discussion
In this study, we have shown that both sEGFR and sHER2 lev-
els change significantly between the times of primary and met-
astatic diagnosis, albeit in opposite directions. We have also
shown that serum EGFR levels are significantly higher in
healthy individuals than in PBC patients. Finally, we found a
rise in serum HER2 expression to be associated with raised
tumour marker levels measured at metastasis.
Furthemore, our results show that a change in sHER2 expres-
sion is a common feature observed between the time of pri-
mary and metastatic diagnosis. In our study, serum HER2
expression changed in 32% of patients. There are several pos-
sible explanations for this. It is increasingly being recognized
that individual breast cancers are composed of biologically
and genetically different clones of cells [16,17]. The capacity
to form metastases may be confined to a particular cellular
clone, which may during the progression of the disease result
in heterogeneity between the primary and metastases.
Another possibility, especially in light of the association
between raised HER2 and tumour marker (CA15.3 and CEA)
expression observed in the present study (Table 3), is that
these changes may simply be a reflection of tumour burden, in
Table 3
Serum oncogene/tumour marker over-expression
Status at metastasis NME EGFR HER2 EGFR or 
HER2
CA15.3 CEA CA15.3 or 
CEA
EGFR or 
HER2, or 
CA15.3 or 
CEA
Number (out of 50) 11 9 29 32 26 11 26 39
% 2 21 85 86 45 22 25 27 8
CA, cancer antigen; CEA, carcinoembryonic antigen; EGFR, epidermal growth factor receptor; HER, human epidermal growth factor receptor; 
NME, no marker elevation.
Table 4
Association between HER2 and EGFR expression and tumour marker expression at metastasis
CA15.3 expression CEA expression
Normal Over-expressed Normal Over-expressed
HER2 expression
Normal 12 5 17 0
O v e r - e x p r e s s e d 1 01 91 91 0
P = 0.019 P = 0.005
EGFR expression
Normal 17 20 29 8
O v e r - e x p r e s s e d 5472
P = 0.718 P = 0.392
CA, cancer antigen; CEA, carcinoembryonic antigen; EGFR, epidermal growth factor receptor; HER, human epidermal growth factor receptor.Breast Cancer Research    Vol 9 No 6    Asgeirsson et al.
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which a certain critical level of cells expressing HER2 is
necessary for its detection in serum [18,19]. Furthermore,
these changes may be a reflection of genetic instability within
the primary tumour. Studies have shown that breast cancer
cells that survive adjuvant treatment may undergo upregulation
or downregulation of some biological markers [20]. Specifi-
cally with regards to upregulation of HER2, Slichenmyer and
Fry [21] and Tanner and coworkers [22] demonstrated this to
occur in breast cancer relapsing after adjuvant hormone
therapy.
In this study we were able to obtain paired tissue samples from
eight patients and, in all, no change in tissue HER2 expression
was observed. Of these, HER2 serum expression at metasta-
sis was normal in seven, although in one (which exhibited tis-
sue over-expression at primary) a change in serum expression
was observed. This may suggest an association between tis-
sue expression at primary and serum expression at metas-
tases, although statistical analysis on such a small group is not
valid. Similar findings have been reported by others in a larger
case series [23]. However, the literature reports conflicting
findings on the expression of HER2 in primary and metastastic
tissue; some studies have identified no difference, whereas
others have shown a difference in up to 26% of cases
[18,22,24,25]. Most of these studies are small case series,
and understandably so because metastatic tissue for analysis
in breast cancer is not readily available. Indeed, this is the only
study, as far as we are aware, whereby an attempt is made to
analyze both serum and tissue of both the primary and metas-
tases in the same patient.
Serum EGFR levels in our group of breast cancer patients
were significantly lower when compared with those in healthy
control individuals. Although this observation is supported by
others [6], it is noteworthy that in our healthy control group 20
(40.8%) had raised serum EGFR levels. We would have
expected 95% of this group to fall within the reference range,
and it must be assumed that this is due to differences in our
control group and the control group evaluated by Bayer to pro-
duce the reference range. A 95% reference range is based on
a normal distribution of the data, but serum EGFR (as with
tumour markers in general) was not normally distributed in our
control group. Also, our control group included a combination
of women who had normal mammograms as part of the
National Health Service Breast Cancer Screeening Program
and those who had attended a symptomatic breast clinic but
had a normal assessment. It may therefore be that benign
breast diseases effect serum EGFR levels. Finally, differences
in menopausal status between these two groups may have an
influence (see below). However, we have not evaluated this
specifically.
In addition to these findings, a significant decrease in serum
expression of EGFR was observed between the diagnoses of
PBC and of metastatic disease. This phenomenon, whereby a
marker decreases with progression of disease, is not com-
monly seen and suggests that this marker may provide differ-
ent information to that from CA15.3, CEA and HER2. Several
hypotheses for this observation have been proposed. One is
that the proteolytic cleavage of the extracellular domain of the
EGFR receptor decreases as normal cells progress to cancer
cells. It has also been suggested that that this may be related
to the association between circulating serum oestrogen and
serum EGFR levels shown in several studies. In a study con-
ducted by Baron and colleagues postmenopausal women had
significantly lower sEGFR levels than did premenopausal
women [13]. Also, in another study conducted by Lafky and
coworkers [26] in metastatic breast cancer patients treated
with an aromatase inhibitor (letrozole), post-treatment serum
EGFR levels (measured at 1 and 3 months) were significantly
lower than pretreatment levels.
In our study, patients who were ER positive and on hormone
treatment with tamoxifen at the time of metastatic diagnosis
were significantly less likely to exhibit a reduction in serum
EGFR levels when compared with patients who were not
receiving treatment (Table 2). The fact that tamoxifen does not
appear to decrease serum oestrogen levels may in part explain
this observation [27], as discussed above. In addition, there is
an inherent selection bias in this group, because patients not
on treatment probably had a longer disease-free interval and
were therefore potentially more likely to have gone from being
premenopausal at primary diagnosis to postmenopausal at
metastasis. However, this was not assessed specifically in our
study. We were able to evaluate five paired tissue samples for
EGFR expression, and in this small group of samples only one
ehibited a definitive change from no expression to positive
expression (on membrane expression analysis). Although only
a very small number of samples was included in this analysis,
we did not observed the same trend toward a reduction in
expression as observed in serum.
Contradictory findings have been reported in the literature with
regard to the prognostic information provided by serum EGFR
assessments, because some have shown low levels to be of
importance whereas others suggest the contrary [6,23,26].
However, until it can be established exactly what serum EGFR
is measuring, it is not as useful a clinical tool as serum HER2
[3].
ErbB receptors exist as plasma membrane monomers. After
binding of the appropriate soluble extracellular ligand, the
monomeric receptors dimerize and become functionally active.
They can form homodimers or heterodimers with other mem-
bers of the ErbB family, and recent studies have shown that
there is considerable crosstalk (cross-phosphorylation)
between the EGFR and HER2 receptors [28]. It has been pos-
tulated that this crosstalk could explain trastuzumab resist-
ance in some HER2-positive patients and that by preventing
this cross-talk (with EGFR inhibition) the efficacy ofAvailable online http://breast-cancer-research.com/content/9/6/R75
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trastuzumab may be enhanced [5]. In our study, EGFR levels
were elevated in 21% of metastatic breast cancer patients,
and in 12% serum levels of both EGFR and HER2 were ele-
vated. This group of patients is of interest because in vitro
studies suggest that they may gain particular benefit from the
combination of anti-EGFR and anti-HER2 treatment [29].
Addition of assessment of serum HER2 and serum EGFR to
CEA and CA15.3 into a 'tumour marker profile' significantly
increases the chances that one of these markers will be raised
(52% to 78%; Table 3). This is in agreement with other studies
and may be helpful in the early diagnosis of tumour recurrence
or metastases or to assess response to treatment [30,31]. At
the present time, however, the use of tumor markers for this
purpose in breast cancer patients is not recommended,
according to international guidelines.
Conclusion
This study shows that, in a number of breast cancer patients,
serum levels of the oncogenes HER2 and EGFR change sig-
nificantly between primary diagnosis and the onset of meta-
static disease, albeit in opposite directions. Decisions on use
of targeted therapies in the metastatic setting are often based
on the oncogene expression of the primary tumour. More con-
troversial is whether elevated serum HER2 and/or serum
EGFR levels might be used to select patients for targeted ther-
apies, even if the primary tumour tissue did not over-express
these oncogenes. This is an important question that almost
certainly will require a multi-institutional study to address.
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